Active Filter(s):
Details:
The Series B funds will funnel into two programs Blood stem cell-based therapy, slated to hit the clinic in 2024 - transfusion-dependent beta-thalassemia (TDBT) in Europe and bone marrow failure syndrome in Europe, South America and North America
Lead Product(s): Blood Stem cell-based Therapy
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $62.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 07, 2023